We live in an exciting era in the field of oncology. Innovative efforts are accelerating cancer research and enabling a new generation of therapeutic and diagnostic technologies to help us improve the ...

When it comes to prostate cancer, there’s a lot of confusion and guesswork floating around—especially among men who don’t like talking about health until something goes wrong. From believing only ...

Kidney cancer, though less common, demands specialized support, particularly as patients on second- and third-line therapies require long-term holistic care. Therapies for kidney cancer have ...

Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A four-part CE activity was launched live-online in December ...

Prostate cancer is one of the most common cancers among men, but spotting it early can make all the difference. Dr. Ravi Chandran K, Consultant, Uro Oncology and Robotic Surgery, Apollo Hospitals, ...

Pantoprazole affecting docetaxel resistance pathways via autophagy (PANDORA): a phase II trial in men with castration resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract from the 2016 ...

Aura Biosciences will present Phase 1 data on bel-sar for bladder cancer at the EAU Congress and host an investor event. Aura Biosciences, Inc. announced its participation in the 40th Annual European ...

Ex-Novartis Oncology CEO Liz Barrett has joined UroGen Pharma. Barrett is taking over as CEO of the uro-oncology specialist at a time when it is working on a rolling NDA that could lead to its first ...

Michigan's largest physician-owned oncology and hematology practice, announced the expansion of its specialty care offerings with the addition of urology services in Michigan. CHC welcomes two ...